Professor Weber is the Deputy Director of the Laura and Isaac Perlmutter Cancer Center (PCC), and works with a multidisciplinary team of medical and surgical oncologists, dermatologists, and pathologists to treat patients with melanomas ranging from the most common early lesions to the most complex. He serves as co-director of PCC’s Melanoma Research Program, and is head of Experimental Therapeutics at PCC, overseeing work in early developmental therapeutics.
Professor Weber’s clinical and research interests primarily lie in the field of immunotherapy for cancer. He works at the forefront of new ideas in immunotherapy for treating patients with melanoma and managing the side effects of these novel therapies. He has been instrumental in the development of ipilimumab for melanoma, publishing some of the earliest papers showing its efficacy, and has been an early advocate for the use of checkpoint inhibition as adjuvant treatment, culminating in the publication of the New England Journal of Medicine work showing benefit for the PD-1 antibody nivolumab compared to ipilimumab for resected high risk melanoma. He has also been involved in a large variety of clinical trials, including trials for melanoma vaccines, protocols involving adoptive cell therapy, and novel immunotherapy trials for patients with melanoma.
Professor Weber is the principal investigator of a number of ongoing studies funded by the National Cancer Institute (NCI), including trials in clinical drug development and managing the autoimmune side effects of immunotherapy for melanoma. He has been the chair of the CONC study section of NCI and of the VA’s Clinical Oncology study section. He also serves as the co-principal investigator of NYU’s Specialized Programs of Research Excellence (SPORE) grant for skin cancer and melanoma research from the National Cancer Institute. His research has been funded by RO1 grants from the NCI for over 28 years.
Professor Weber has published more than 250 articles in the top peer-reviewed journals in his field. He currently sits on the scientific advisory boards of seven cancer-related biotechnology companies and numerous cancer institutions and foundations.